Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study.

Hassan S, Milman U, Feld J, Eder L, Lavi I, Cohen S, Zisman D.

Arthritis Res Ther. 2016 Nov 10;18(1):261.

2.

Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices.

Sakthiswary R, Syahrul Sazliyana S, Mohd Shahrir MS, Shahril NS, Hussein H.

EXCLI J. 2012 Apr 2;11:142-9. eCollection 2012.

3.

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.

Gabay C, McInnes IB, Kavanaugh A, Tuckwell K, Klearman M, Pulley J, Sattar N.

Ann Rheum Dis. 2016 Oct;75(10):1806-12. doi: 10.1136/annrheumdis-2015-207872. Epub 2015 Nov 27.

4.

Role of the NLRP3 inflammasome in the transient release of IL-1β induced by monosodium urate crystals in human fibroblast-like synoviocytes.

Zheng SC, Zhu XX, Xue Y, Zhang LH, Zou HJ, Qiu JH, Liu Q.

J Inflamm (Lond). 2015 Apr 10;12:30. doi: 10.1186/s12950-015-0070-7. eCollection 2015.

5.

Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy.

Rodriguez-Jimenez NA, Garcia-Gonzalez CE, Ayala-Lopez KP, Trujillo-Hernandez B, Aguilar-Chavez EA, Rocha-Muñoz AD, Vasquez-Jimenez JC, Olivas-Flores E, Salazar-Paramo M, Corona-Sanchez EG, Vazquez-Del Mercado M, Varon-Villalpando E, Cota-Sanchez A, Cardona-Muñoz EG, Gamez-Nava JI, Gonzalez-Lopez L.

Biomed Res Int. 2014;2014:510305. doi: 10.1155/2014/510305. Epub 2014 Aug 27.

6.

From synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis.

Choi IY, Gerlag DM, Holzinger D, Roth J, Tak PP.

PLoS One. 2014 Aug 28;9(8):e106253. doi: 10.1371/journal.pone.0106253. eCollection 2014.

7.

Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.

Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M.

Rheumatology (Oxford). 2014 Dec;53(12):2143-54. doi: 10.1093/rheumatology/keu224. Epub 2014 Jun 6. Review.

8.

FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis.

Ramos MI, Perez SG, Aarrass S, Helder B, Broekstra P, Gerlag DM, Reedquist KA, Tak PP, Lebre MC.

Arthritis Res Ther. 2013;15(6):R209.

9.

Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation.

Herenius MM, Oliveira AS, Wijbrandts CA, Gerlag DM, Tak PP, Lebre MC.

PLoS One. 2013;8(2):e57802. doi: 10.1371/journal.pone.0057802. Epub 2013 Feb 27.

10.

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.

Kirkham BW, Wasko MC, Hsia EC, Fleischmann RM, Genovese MC, Matteson EL, Liu H, Rahman MU.

Ann Rheum Dis. 2014 Jan;73(1):161-9. doi: 10.1136/annrheumdis-2012-202089. Epub 2013 Jan 7.

11.
12.

Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Curtis JR, John A, Baser O.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1282-91. doi: 10.1002/acr.21693.

13.

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis.

Klaasen R, Herenius MM, Wijbrandts CA, de Jager W, van Tuyl LH, Nurmohamed MT, Prakken BJ, Gerlag DM, Tak PP.

Ann Rheum Dis. 2012 Sep;71(9):1510-6. doi: 10.1136/annrheumdis-2011-200646. Epub 2012 Mar 22.

14.

Macrophage migration inhibitory factor: a multifunctional cytokine in rheumatic diseases.

Kasama T, Ohtsuka K, Sato M, Takahashi R, Wakabayashi K, Kobayashi K.

Arthritis. 2010;2010:106202. doi: 10.1155/2010/106202. Epub 2010 Dec 26.

15.

Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids.

Olendzki BC, Leung K, Van Buskirk S, Reed G, Zurier RB.

Evid Based Complement Alternat Med. 2011;2011:827286. doi: 10.1155/2011/827286. Epub 2011 Oct 9.

16.
17.

Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.

Bruchfeld A, Carrero JJ, Qureshi AR, Lindholm B, Barany P, Heimburger O, Hu M, Lin X, Stenvinkel P, Miller EJ.

Mol Med. 2009 Mar-Apr;15(3-4):70-5. doi: 10.2119/molmed.2008.00109. Epub 2009 Dec 8.

Supplemental Content

Support Center